Precision genetic medicines delivered via a proprietary non‑viral nanoparticle platform that targets specific cell types—including immune cells and select heart, lung, and CNS tissues—to deliver mRNA and other genetic payloads. Therapeutic pipeline focused on autoimmune diseases and oncology, with a lead program to restore immune tolerance in type 1 diabetes advancing into IND‑enabling studies.